HC Wainwright Predicts Journey Medical Q1 Earnings

Journey Medical Corporation (NASDAQ:DERM) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical’s Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $1.76 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $2.01 EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Journey Medical presently has an average rating of “Hold” and an average price target of $13.00.

Journey Medical Stock Down 30.0%

DERM opened at $4.78 on Friday. The stock has a market cap of $158.97 million, a price-to-earnings ratio of -10.17 and a beta of 0.81. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42. The firm’s fifty day moving average is $8.00 and its 200 day moving average is $7.80. Journey Medical has a fifty-two week low of $4.76 and a fifty-two week high of $9.56.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million during the quarter, compared to analysts’ expectations of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 51.42%.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. J. Goldman & Co LP bought a new stake in shares of Journey Medical during the fourth quarter valued at approximately $6,155,000. Millennium Management LLC purchased a new position in Journey Medical during the fourth quarter valued at $3,530,000. Ikarian Capital LLC purchased a new position in Journey Medical during the fourth quarter valued at $1,939,000. Wasatch Advisors LP increased its holdings in Journey Medical by 23.8% in the 2nd quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company’s stock valued at $8,272,000 after acquiring an additional 221,456 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Journey Medical by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company’s stock valued at $1,884,000 after acquiring an additional 148,612 shares during the last quarter. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical News Summary

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Strong Emrosi uptake and FY‑2025 results: Management reported FY2025 revenue of $61.9M, Emrosi generated $14.7M in net revenues with ~53,000 prescriptions filled since its April 2025 launch, and payer access now covers >100M U.S. commercial lives — data that support faster revenue scaling and path to profitability. GlobeNewswire: Full‑Year 2025 Results
• Positive Sentiment: HC Wainwright reiterates Buy and $13 price target with bullish long‑term EPS trajectory: The firm keeps a Buy rating and projects multi‑year EPS growth (FY2027–FY2030 forecasts rising to $1.16 → $2.01), which supports investor optimism about valuation upside versus current levels. MarketBeat: Analyst Note (HC Wainwright)
• Neutral Sentiment: Q4 2025 EPS beat but revenue missed: Journey reported Q4 EPS of ($0.04), beating consensus (‑$0.06) by $0.02, yet revenue of $16.08M missed estimates (~$18.86M). The EPS beat eases near-term concerns, but the top‑line shortfall highlights execution and adoption timing risks. MarketBeat: Q4 Earnings & Call
• Negative Sentiment: HC Wainwright trims some medium‑term estimates: Although still constructive, the firm lowered FY2026–FY2030 estimates slightly (e.g., FY2026 to $0.16 from $0.18; small downticks to FY2027–FY2029 forecasts), indicating tempered near‑term margin/volume assumptions that could limit immediate upside. MarketBeat: Analyst Revisions

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.